PF 06835919

Drug Profile

PF 06835919

Alternative Names: PF-06835919

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 31 Jan 2017 Phase-I clinical trials in Non-alcoholic steatohepatitis (PO) before January 2017 (Pfizer pipeline, January 2017)
  • 23 Jan 2017 Pfizer plans a phase I trial in Healthy volunteers in Belgium (PO) (NCT03031119)
  • 01 Jan 2017 Pfizer completes a phase I trial in Non-alcoholic fatty liver disease (In volunteers) in USA (NCT02974374)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top